Actavis Group’s U.S. division, Actavis Totowa LLC, has recalled all lots of heart failure treatment Digitek (digoxin tablets). The company announced the Class I nationwide recall for Digitek after the possible commercial release of tablets with twice the approved level of the active ingredient, posing a risk of digitalis toxicity in patients with renal failure. Digitalis toxicity can cause nausea, vomiting, dizziness, low blood pressure, cardiac instability, bradycardia and death.